Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm done with this penny stock market bullshit. The cons can have it.
Form 4 Filed on 9/1/2010 - Looks like the CEO is helping alleviate Barron of some of their stock. Always a good sign when the CEO puts his money where his mouth is.
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
Parlontieri Richard A 2. Issuer Name and Ticker or Trading Symbol
SPEEDEMISSIONS INC [ SPMI ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__ X __ Director _____ 10% Owner
__ X __ Officer (give title below) _____ Other (specify below)
CEO, President
(Last) (First) (Middle)
106 NORTH COVE DRIVE 3. Date of Earliest Transaction (MM/DD/YYYY)
8/30/2010
(Street)
PEACHTREE CITY, GA 30269
(City) (State) (Zip) 4. If Amendment, Date Original Filed (MM/DD/YYYY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 8/30/2010 P 370601 A $0.0152 757843 D
Common Stock 8/31/2010 P 55000 A $0.0152 812843 D
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Parlontieri Richard A
106 NORTH COVE DRIVE
PEACHTREE CITY, GA 30269 X
CEO, President
Signatures
Richard A. Parlontieri by Michael S. Shanahan, Attorney-in-Fact 9/1/2010
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Alright. I'm going to revisit this one. Simply seems too undervalued to pass up.
Dare I say this is the calm before the storm?
I took a small position and was watching the level 2 on this today. Everytime the stock price upticked...HDSN would undercut the ask to sell his shares. That's what I mean when I say axe.
HDSN seems like a bit of a thorn here. Once he's out of the stock it should move easily
RMDT creeping up slow and steady
RMDT still on the radar.
RMDT getting some action into the close
hmmm...the way ADSY is trading reminds me of the group that did NTMG
um yeah. Look at the one year chart. 0 volume and then in the last 7 days...KABOOM...thing starts trading millions of dollars
somebody playing this thing like a violin.
At any rate, I saw there was a gap at $.0375 and put my first order there...feels good when you get your order filled at low of day and they start walking it back up :)
ADSY looks like something serious.
ADSY $.0375 gap filled. Someone with some serious punch has been on this one the last week.
RMDT getting some nice action into the close
RMDT float appears to be under accumulation
Keep RMDT on your radar over the next week or two...
RMDT bouncing back
SIRG - had to watch the train leave without me on this one. Didn't like the way L2 was looking when it first opened up...of course all of that has since changed lol
Arena Pharmaceuticals Announces Second Quarter 2010 Financial Results and Recent DevelopmentsLast update: 8/3/2010 4:03:00 PMFDA Completes Successful Pre-Approval Inspection of Arena's Swiss Manufacturing Facility - SAN DIEGO, Aug. 3, 2010 /PRNewswire via COMTEX/ -- Arena Pharmaceuticals, Inc. (ARNA) today reported financial results for the second quarter ended June 30, 2010, and recent developments, including the successful Pre-Approval Inspection, or PAI, of the company's Swiss drug product manufacturing facility by the US Food and Drug Administration, or FDA. "We have recently achieved a number of important milestones, including the establishment of an agreement with Eisai for the commercialization of lorcaserin in the US, the successful completion of the FDA's pre-approval inspection of our Swiss manufacturing facility and the publication of our BLOOM trial results in the New England Journal of Medicine," stated Jack Lief, Arena's President and Chief Executive Officer. "We are continuing to execute on our plans for lorcaserin as we prepare for the September FDA advisory committee meeting and potential regulatory approval." Arena reported a lower net loss in the second quarter of 2010 of $28.8 million, or $0.28 per share, compared to a net loss in the second quarter of 2009 of $38.0 million, or $0.48 per share, and a lower net loss in the first half of 2010 of $60.0 million, or $0.60 per share, compared to a net loss in the first half of 2009 of $88.6 million, or $1.16 per share. As expected, research and development expenses declined to $20.5 million in the second quarter of 2010 from $24.2 million in the second quarter of 2009. Research and development expenses in the first half of 2010 declined to $38.8 million from $66.8 million in the first half of 2009. This decrease is primarily attributable to the completion of the pivotal Phase 3 clinical trials for lorcaserin. Research and development expenses included $1.8 million in non-cash, share-based compensation expense in the first half of both 2010 and 2009. General and administrative expenses totaled $6.8 million in the second quarter of 2010, compared to $5.7 million in the second quarter of 2009, and $13.8 million in the first half of 2010, compared to $13.3 million in the first half of 2009. This increase in general and administrative expenses is primarily attributable to increased market research expenses. General and administrative expenses in the first half of 2010 included $1.3 million in non-cash, share-based compensation expense, compared to $1.6 million in the first half of 2009. Interest expense of $9.9 million was recorded in the first half of 2010, compared to $3.7 million in the first half of 2009. This increase is primarily attributable to the loan Arena received from Deerfield Management in July 2009. At June 30, 2010, cash, cash equivalents and short-term investments totaled $118.5 million and approximately 112.3 million shares of common stock were outstanding. In July 2010, Arena received an upfront payment of $50.0 million from Eisai Inc., or Eisai, under a marketing and supply agreement for lorcaserin. Arena's Recent Developments Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, entered into a marketing and supply agreement with Eisai for the commercialization of lorcaserin in the United States following FDA approval. Eisai was established in 1995 and is ranked among the top-20 US pharmaceutical companies (based on retail sales). Eisai began marketing its first product in the United States in 1997 and has grown to become a fully-integrated pharmaceutical business with fiscal year 2009 sales of approximately $3.9 billion. Under the terms of the marketing and supply agreement, Arena received an upfront payment of $50.0 million from Eisai, and, upon regulatory approval and the delivery of product supply for launch, Arena may receive up to an additional $90.0 million in milestone payments depending on the label and timing of approval. Arena will manufacture lorcaserin at its facility in Switzerland and sell finished product to Eisai for a purchase price of 31.5% - 36.5% of Eisai's annual net product sales. Arena is also eligible to receive $1.16 billion in purchase price adjustment payments based on annual sales levels of lorcaserin and up to an additional $70.0 million in regulatory and development milestone payments. The FDA completed the PAI of Arena's drug product manufacturing facility in Switzerland and classified the inspection as No Action Indicated, or NAI, with no Form 483 issued. In addition to this PAI, one of Arena's contract manufacturing organizations for lorcaserin active pharmaceutical ingredient, Siegfried Ltd., was also inspected by the FDA, and the inspection was also classified as NAI with no Form 483 issued. These successful PAIs enable Arena to manufacture finished product for marketing and distribution following regulatory approval. Results from the two-year, pivotal Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial were published in the July 15, 2010, issue of the New England Journal of Medicine. The data presented in the article show that lorcaserin used in conjunction with behavioral modification caused significantly greater weight loss and improved maintenance of weight loss compared to placebo. Lorcaserin also improved values for biomarkers that may be predictive of future cardiovascular events, including lipid levels, insulin resistance, levels of inflammatory markers and blood pressure. The FDA notified Arena of the tentative scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application, or NDA. At the American Diabetes Association's 70th Scientific Sessions, pooled Week 52 data from lorcaserin's pivotal Phase 3 clinical trial program were presented. Data from over 6,000 patients show that more than twice as many lorcaserin patients (47.1%) achieved at least 5% body weight loss compared to placebo (22.6%) using Intent-to-Treat with Last Observation Carried Forward analysis. Lorcaserin reduced body weight in all patient subgroups evaluated, as defined by gender, age, ethnicity, starting body weight and starting Body Mass Index, or BMI. Greater improvements in cardiovascular risk factors were also achieved with lorcaserin treatment compared to placebo overall and in most subgroups. Patients in both the lorcaserin and placebo groups who decreased their body weight by at least 5% achieved more favorable changes in lipid parameters, glycemic parameters, blood pressure and high sensitivity C-reactive protein as compared to those who had less than 5% weight loss. Greater improvements in these cardiovascular risk factors were also achieved by patients who entered the studies with values indicative of elevated risk. Arena received net proceeds of $35.5 million in June 2010 from the sale of 11.0 million shares of common stock to Deerfield Management at a price of $3.23 per share. As part of the transaction, the exercise price of 16.2 million of the 28.0 million outstanding warrants to purchase common stock that Deerfield previously received in connection with a June 2009 loan to Arena were reduced from $5.42 to $3.45 per share. 2010 Financial Guidance Arena reported that it expects to end 2010 with $112 million to $122 million in cash, cash equivalents and short-term investments, reflecting receipt in July 2010 of the $50 million upfront payment from Eisai, and also increased revenue guidance from a range of $12 million to $14 million to a range of $14 million to $16 million to reflect the 2010 amortization of such upfront payment. Both cash and revenue guidance excludes any potential milestones from Eisai and other existing collaborations, revenue from any new collaborations in 2010 and any commercial sales of lorcaserin. Arena decreased its 2010 guidance for general and administrative expenses from a range of $31 million to $35 million to a range of $26 million to $30 million (including non-cash expenses of approximately $3 million) primarily to reflect lower anticipated marketing costs for lorcaserin. Arena reiterated the following other components of its full year guidance: external clinical and preclinical study fees and expenses, including manufacturing, of approximately $17 million to $21 million; internal research and development expenses of approximately $57 million to $63 million (including non-cash expenses of approximately $10 million); and capital expenditures of approximately $7 million. Scheduled Earnings Call Arena will host both a conference call and webcast to discuss the second quarter 2010 financial results and to provide a business and financial update today, Tuesday, August 3, 2010, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Jack Lief, President and Chief Executive Officer, and Robert E. Hoffman, Vice President, Finance and Chief Financial Officer, will host the conference call. The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Second Quarter 2010 Conference Call." The conference call will be webcast live under the investor relations section of Arena's website at , and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. About Arena Pharmaceuticals Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management and has completed a pivotal Phase 3 clinical trial program. Arena has filed an NDA for lorcaserin, and the FDA has assigned a PDUFA date of October 22, 2010, for review of the application. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States. Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development. Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the significance of the marketing and supply agreement with Eisai, the FDA's pre-approval inspections, and the publication of BLOOM trial results; rights and obligations under the marketing and supply agreement with Eisai and expectations, goals and future activities related to such agreement; the September 2009 FDA advisory committee meeting; the advancement, therapeutic indication and use, safety, efficacy, tolerability, potential, regulatory review and potential regulatory approval and commercial launch of lorcaserin; the significance of biomarkers; financial guidance; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds, commercialize drugs and execute its plans. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks related to the implementation and continuation of the marketing and supply agreement with Eisai and dependence on Eisai for commercialization of lorcaserin in the United States; regulatory authorities or advisors may not find data from Arena's clinical trials and other studies sufficient for regulatory approval; the timing and ability of Arena to receive regulatory approval for its drug candidates; the ability to enter into agreements to develop or commercialize lorcaserin and other of Arena's compounds or programs; Arena's ability to commercialize lorcaserin outside of the United States with another company or independently; the timing, success and cost of the lorcaserin program and other of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Eisai and Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Arena Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts) Three months ended Six months ended June 30, June 30, -------- -------- 2010 2009 2010 2009 ---- ---- ---- ---- (unaudited) (unaudited) Revenues Manufacturing services $1,437 $1,508 $3,412 $2,926 Collaborative agreements 1,022 920 1,560 2,160 ----- --- ----- ----- Total revenues 2,459 2,428 4,972 5,086 Operating Expenses Cost of manufacturing services 1,630 1,643 3,495 2,997 Research and development 20,502 24,205 38,816 66,825 General and administrative 6,760 5,660 13,774 13,302 Restructuring charges - 3,324 - 3,324 Amortization of acquired technology & other intangibles 531 573 1,068 1,139 --- --- ----- ----- Total operating expenses 29,423 35,405 57,153 87,587 Interest and Other Income (Expense) Interest income 92 46 231 216 Interest expense (2,281) (1,935) (9,931) (3,652) Gain (Loss) from valuation of derivative liabilities 415 (2,492) 1,834 (2,127) Other (19) (625) 20 (533) --- ---- --- ---- Total interest and other expense, net (1,793) (5,006) (7,846) (6,096) ------ ------ ------ ------ Net loss $(28,757) $(37,983) $(60,027) $(88,597) ======== ======== ======== ======== Net loss per share, basic and diluted $(0.28) $(0.48) $(0.60) $(1.16) ====== ====== ====== ====== Shares used in calculating net loss per share, basic and diluted 104,136 79,212 99,571 76,701 ======= ====== ====== ====== Arena Pharmaceuticals, Inc. Condensed Consolidated Balance Sheet Data (In thousands) December 31, June 30, 2010 2009 ------------- ------------- (unaudited) * Assets Cash, cash equivalents & short-term investments $118,498 $115,449 Accounts receivable 1,900 1,415 Other current assets 4,220 4,409 Land, property & equipment, net 92,090 95,445 Acquired technology & other non- current assets 18,142 19,560 ------ ------ Total assets $234,850 $236,278 ======== ======== Liabilities and Stockholders' Equity Accounts payable and accrued liabilities $11,356 $15,884 Total deferred revenues 4,070 4,086 Total derivative liabilities 4,808 6,642 Total note payable to Siegfried 8,827 9,143 Note payable to Deerfield** 50,470 47,906 Total lease financing obligations & other long-term liabilities 77,653 78,050 Total stockholders' equity 77,666 74,567 ------ ------ Total liabilities & stockholders' equity $234,850 $236,278 ======== ======== * The condensed consolidated balance sheet data as of December 31, 2009, has been derived from the audited financial statements as of that date. ** The outstanding principal balance of the note payable to Deerfield at June 30, 2010, and December 31, 2009, was $90.0 million. Contact: Arena Pharmaceuticals, Inc. Media Contact: Russo Partners Jack Lief David Schull, President President and CEO david.schull@russopartnersllc.com 858.717.2310 Cindy McGee Manager, IR and Corporate Communications Anthony J. Russo, Ph.D., CEO 858.453.7200, ext. 1479 tony.russo@russopartnersllc.com 212.845.4251 ------------------SOURCE Arena Pharmaceuticals, Inc. Copyright (C) 2010 PR Newswire. All rights reserved
RMDT on the radar
FROI - the bloodbath continues
CRPZ reminds me of a fat kid trying to run up 12 flights of stairs...like a really really fat kid
Ouch that sucks.
Black Horse Capital (a large shareholder in LNET owning more than 10%) has been unloading per the recent Form 4's. I currently have an open short position as I think this is heading lower.
Tim Sykes shorting HSWI
VRNM was a nice short today...also thinking LNET is headed lower...Black Horse Capital Management (a major shareholder owning more than 10%) has been unloading LNET per the recent Form 4's...
yup...something just didn't seem right with it which is why I went short at $3.88 avg...also short on LNET...appears one of the larger shareholders has been unloading lately (Black horse)
Well, BP needs to worry about bailing their own asses out rather than running around purchasing worthless companies.
from VRNM's last 10-Q
Total assets
$ 149,426
Total revenues
$ 13,031
$98 million seems like a high price tag
BEWARE: BP Biofuels North America LLC is NOT the same company as BP Plc nor are they affiliated.
Look at the balance sheet. Less than $12,000 in revenues last quarter. Not to mention, the "BP" in the press release that everyone thinks is involved here is in fact a totally different BP. "BP Biofuels North America LLC" is not BP Plc, which appears to be the mistake people are making
looks like a nice add...bouncing hard now
Global Technologies Notes Obama Call for $5B in Clean Energy Tax Credits: Increases Revenue Projections and Asset Valuation
9:35a ET July 12, 2010 (Market Wire)
Global Technologies, Ltd. (PINKSHEETS: GTLL) announced today it revised upwards the revenue projections and the market value of its core asset holdings based on Presidents Obama's call last Friday for Congress to expand the clean energy tax credits.
Obama told an audience at the University of Nevada that a $5 billion increase in clean energy manufacturing could generate nearly 40,000 jobs.
Through its pioneering Innovation Development & Demonstration (ID2) Partnership, GTL focuses on the acquisition and development of nascent innovations, inventions and Intellectual Property (IP). Of key interest to the Company are operations and technology holdings in the sustainable energy and environmental sectors.
The Company has moved quickly to increase the market value of the asset value and advance the income projections of the $15,000,000 acquisitions of its initial fifteen (15) Intellectual Property (IP) Assets acquired from CLE's extensive IP holdings, through an equity-building issuance of Preferred Stock that created no debt for the Company.
Development Projects have now been launched for all of the first nine (9) core Wind Turbine Blade Design technologies and has signed a $15,000,000 Intellectual Property (IP) Development & Distribution License with the Wind Design Distribution Group (WDD), a UK Limited Partnership, for development and distribution the first of its proprietary Wind Turbine Blade Designs.
All of these initiatives will benefit directly from the $5 billion clean energy tax credits.
The Company will continue to provide updates as these projects progress though the stages of its pioneering Innovation Development & Demonstration (ID2) Matrix. The Company has further licensing agreements and development projects to emerge from these core assets as the analysis and prioritization process continues.
The Company has recently announced the launch its international licensing and distribution program for its portfolio of technology and solutions. The licensing program affords worldwide partners the ability to obtain access to, and distribution rights to, Global Tech's portfolio and solutions.
The new licensing program furthers the Company's expansion and business strategy for 2010; to aggressively acquire, develop, license and expand new technologies and operations as part of its enhanced business plan and strategic operational focus.
Through its pioneering Innovation Development & Demonstration (ID2) Partnership, GTL focuses on the acquisition and development of nascent innovations, inventions and Intellectual Property (IP). Of key interest to the Company are operations and technology holdings in the sustainable energy and environmental sectors.
The Company builds revenues and asset value through a model of continuous growth, income from or sale of its portfolio holdings, joint development agreements and technology licensing or distribution agreements.
About Global Technologies, Ltd. GLOBAL TECHNOLOGIES (GTL) is a technology portfolio company that acquires nascent technology and related innovations, inventions and IP assets to enhance their growth and development. The company builds revenues and asset value through a model of continuous growth, income from or sale of its portfolio holdings, and technology licensing or distribution agreements.
GTL invests primarily in innovative and promising clean/renewable energy or bio-tech technologies that have reached the stage in the critical Technology Development & Demonstration phase of the Innovative Cycle, which includes Prototype, Demonstration and Market Analysis.
Safe-Harbor This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated on the Company's website "Investors" section by reference) and should be read before any investment decision.
Contact:
Global Technologies, Ltd.
www.GlobalTechnologiesLtd.com
Investor Relations
Phone Tel: (44) 0207 078 3972
Fax: (44) 0207 990 8465
Email: info@GlobalTechnologiesLtd.com
SOURCE: Global Technologies, Ltd.
http://www.GlobalTechnologiesLtd.com
mailto:info@GlobalTechnologiesLtd.com
GTLL puts out news and no one cares lol
Global Technologies Notes Obama Call for $5B in Clean Energy Tax Credits: Increases Revenue Projections and Asset Valuation
9:35a ET July 12, 2010 (Market Wire)
Global Technologies, Ltd. (PINKSHEETS: GTLL) announced today it revised upwards the revenue projections and the market value of its core asset holdings based on Presidents Obama's call last Friday for Congress to expand the clean energy tax credits.
Obama told an audience at the University of Nevada that a $5 billion increase in clean energy manufacturing could generate nearly 40,000 jobs.
Through its pioneering Innovation Development & Demonstration (ID2) Partnership, GTL focuses on the acquisition and development of nascent innovations, inventions and Intellectual Property (IP). Of key interest to the Company are operations and technology holdings in the sustainable energy and environmental sectors.
The Company has moved quickly to increase the market value of the asset value and advance the income projections of the $15,000,000 acquisitions of its initial fifteen (15) Intellectual Property (IP) Assets acquired from CLE's extensive IP holdings, through an equity-building issuance of Preferred Stock that created no debt for the Company.
Development Projects have now been launched for all of the first nine (9) core Wind Turbine Blade Design technologies and has signed a $15,000,000 Intellectual Property (IP) Development & Distribution License with the Wind Design Distribution Group (WDD), a UK Limited Partnership, for development and distribution the first of its proprietary Wind Turbine Blade Designs.
All of these initiatives will benefit directly from the $5 billion clean energy tax credits.
The Company will continue to provide updates as these projects progress though the stages of its pioneering Innovation Development & Demonstration (ID2) Matrix. The Company has further licensing agreements and development projects to emerge from these core assets as the analysis and prioritization process continues.
The Company has recently announced the launch its international licensing and distribution program for its portfolio of technology and solutions. The licensing program affords worldwide partners the ability to obtain access to, and distribution rights to, Global Tech's portfolio and solutions.
The new licensing program furthers the Company's expansion and business strategy for 2010; to aggressively acquire, develop, license and expand new technologies and operations as part of its enhanced business plan and strategic operational focus.
Through its pioneering Innovation Development & Demonstration (ID2) Partnership, GTL focuses on the acquisition and development of nascent innovations, inventions and Intellectual Property (IP). Of key interest to the Company are operations and technology holdings in the sustainable energy and environmental sectors.
The Company builds revenues and asset value through a model of continuous growth, income from or sale of its portfolio holdings, joint development agreements and technology licensing or distribution agreements.
About Global Technologies, Ltd. GLOBAL TECHNOLOGIES (GTL) is a technology portfolio company that acquires nascent technology and related innovations, inventions and IP assets to enhance their growth and development. The company builds revenues and asset value through a model of continuous growth, income from or sale of its portfolio holdings, and technology licensing or distribution agreements.
GTL invests primarily in innovative and promising clean/renewable energy or bio-tech technologies that have reached the stage in the critical Technology Development & Demonstration phase of the Innovative Cycle, which includes Prototype, Demonstration and Market Analysis.
Safe-Harbor This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated on the Company's website "Investors" section by reference) and should be read before any investment decision.
Contact:
Global Technologies, Ltd.
www.GlobalTechnologiesLtd.com
Investor Relations
Phone Tel: (44) 0207 078 3972
Fax: (44) 0207 990 8465
Email: info@GlobalTechnologiesLtd.com
SOURCE: Global Technologies, Ltd.
http://www.GlobalTechnologiesLtd.com
mailto:info@GlobalTechnologiesLtd.com
what an absolute POS this play turned out to be.
EFGU added $.021's...should bounce once HDSN and LFCM are out of the picture
EFGU on the radar for a bounce
DNDT on radar here...someone's loading up on the $.05's looks like
Take a look at RLGT. Looks like someone placed a large bet (around $200K) at $.28 yesterday. No recent news or filings which leads me to believe that something may be up...keep it on radar just in case.